Trademark: 97626317
Word
PHENO LOCK
Status
Registered
Status Code
700
Status Date
Tuesday, October 24, 2023
Serial Number
97626317
Registration Number
7201861
Registration Date
Tuesday, October 24, 2023
Mark Type
4000
Filing Date
Monday, October 10, 2022
Published for Opposition
Tuesday, August 8, 2023

Trademark Owner History
Quell Therapeutics Limited - Original Registrant

Classifications
40 Pharmaceutical manufacturing and processing; biological, biotechnological and biopharmaceutical manufacturing and manufacturing processing; manufacturing processing of biological tissue, blood, cell and genetic material; viral vector production, namely manufacture; gene therapy production, namely manufacture; custom manufacture of pharmaceutical and biological formulations and products; processing and modification of human and animal cells in the custom manufacture of pharmaceutical and biological formulations and products
5 Pharmaceutical and biological preparations for diagnostic, medical, therapeutic and prophylactic use, namely, for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; pharmaceutical, medical and veterinary preparations for diagnostic, therapeutic and prophylactic purposes, namely, for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; pharmaceutical preparations for cell therapy; pharmaceutical preparations for gene therapy; pharmaceutical preparations for genetically modifying human and animal cells for diagnostic and medical purposes; human and animal cells and parts, namely, stem cells thereof for medical and veterinary purposes; T cells for medical and veterinary purposes; regulatory T cells for medical and veterinary purposes; preparations of blood or cells extracted from humans and animals which have been adapted for therapeutic purposes; pharmaceutical, medical and clinical preparations for use in treatment, amelioration and prophylaxis of diseases, disorders and suppression of the immune system; immunological agents and preparations for medical purposes; pharmaceutical preparations for therapies to modulate the immune system; pharmaceutical preparations for therapies for autoimmune conditions and immunological disorders; chimeric antigen receptors and therapeutic preparations for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; [ Colostral antibodies for diagnostic, medical, therapeutic and prophylactic use, namely, for medical conditions caused by the immune system; ] pharmaceutical preparations for therapeutic delivery of nucleic acids; viral vectors for therapeutic and prophylactic purposes for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; nucleic acid vectors for therapeutic and prophylactic purposes for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; medical pharmaceutical preparations containing viral vectors for therapeutic and prophylactic purposes for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; medical preparations containing nucleic acid vectors for therapeutic and prophylactic purposes for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection
1 Class 1: Chemical and biological preparations for use in science and industry; chemical and biological preparations for non-medical purposes; Chemical and biological preparations for genetically modifying human and animal cells for non-medical purposes; reagents for use in the genetic modification of human and animal cells for scientific or medical research use; human and animal cells and parts in the nature of stem cells thereof for scientific and research purposes; T cells for scientific and research purposes; regulatory T cells for scientific and research purposes; preparations of blood or cells extracted from humans and animals for scientific and research purposes; immunological agents and preparations for non-medical purposes; chimeric antigen receptors and preparations thereof for scientific and research purposes; antibody reagents used for the detection of antigens in cell and tissue analysis for in vitro diagnostic use for use in science and industry; nucleic acids for laboratory use; nucleic recombinant acids; synthetic deoxyribonucleic acids for scientific purposes; viral vectors for use in science and industry; nucleic acid vectors for use in science and industry
In the statement, line 39 through line 41, "Colostral antibodies for diagnostic, medical, therapeutic and prophylactic use, namely for medical conditions caused by the immune system;" is deleted.

Trademark Events
Feb 13, 2024
Notice Of Updated Registration Confirmation Emailed
Jan 5, 2024
Amendment Under Section 7 - Processed
Jan 4, 2024
Teas Section 7 Request Received
Nov 18, 2023
Case Assigned To Post Registration Paralegal
Oct 31, 2023
Teas Section 7 Request Received
Oct 24, 2023
Notice Of Registration Confirmation Emailed
Oct 24, 2023
Registered-Principal Register
Sep 20, 2023
Changes/Corrections After Pub Approval Entered
Sep 20, 2023
Assigned To Petition Staff
Aug 29, 2023
Teas Post Publication Amendment Received
Aug 8, 2023
Official Gazette Publication Confirmation E-Mailed
Aug 8, 2023
Published For Opposition
Jul 19, 2023
Notification Of Notice Of Publication E-Mailed
Jun 30, 2023
Electronic Record Review Complete
Jun 23, 2023
On Hold - Electronic Record Review Required
Jun 22, 2023
Approved For Pub - Principal Register
Jun 22, 2023
Examiner's Amendment Entered
Jun 22, 2023
Notification Of Examiners Amendment E-Mailed
Jun 22, 2023
Examiners Amendment E-Mailed
Jun 22, 2023
Examiners Amendment -Written
May 20, 2023
Teas/Email Correspondence Entered
May 19, 2023
Correspondence Received In Law Office
May 19, 2023
Teas Response To Office Action Received
Feb 27, 2023
Notification Of Non-Final Action E-Mailed
Feb 27, 2023
Non-Final Action E-Mailed
Feb 27, 2023
Non-Final Action Written
Feb 16, 2023
Assigned To Examiner
Oct 25, 2022
New Application Office Supplied Data Entered
Oct 13, 2022
New Application Entered

Trademark Alertz updated from USPTO on 2030-01-24